EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment. (January 2016)

• Record Type: Journal Article
• Authors: Tsai, Li-Chu; Hsieh, Hao-Ying; Lu, Kun-Ying; Wang, Sin-Yu; Mi, Fwu-Long
• Is Part Of: Nanomedicine. Volume 11:Number 1(2016)
• Page Start: 9
• Page End: 30
• Publication Date: 2016-01
• Subjects: cellular uptake -- doxorubicin -- drug release -- EGCG -- gelatin -- gold nanoparticles -- Lam 67R -- MMP-2 -- prostate cancer; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm.15.183
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: Development of epigallocatechin gallate (EGCG) and gelatin-doxorubicin conjugate (GLT-DOX)-coated gold nanoparticles (DOX-GLT/EGCG AuNPs) for fluorescence imaging and inhibition of prostate cancer cell growth.Materials & methods: AuNPs alternatively coated with EGCG and DOX-GLT conjugates were prepared by a layer-by-layer assembly method. The physicochemical properties of the AuNPs and the effect of Laminin 67R receptor-mediated endocytosis on the anticancer efficacy of the AuNPs were examined.Results: The AuNPs significantly inhibit the proliferation of PC-3 cancer cell and the enzyme-responsive intracellular release of DOX could be tracked by monitoring the recovery of the fluorescence signal of DOX.Conclusion: Laminin 67R receptor-mediated delivery of DOX using the AuNPs enhanced cellular uptake of DOX and improved apoptosis of PC-3 cells.